-
NN8640-4245 - A dose-finding trial evaluating the effect and safety of once-weekly treatment of somapacitan compared to daily Norditropin in children with short stature born small for gestational age with no catch-up growth by 2 years of age or older
This research study involves children born small and who stayed small. Treatment is somapacitan once a week compared to Norditropin® once a day. Researchers will ...Phase
Interventional
-
A phase 2 open-label single-arm cohort study to evaluate the safety efficacy and pharmacokinetics of sparsentan treatment in pediatric subjects with selected proteinuric glomerular diseases (EPPIK)
The purpose of this research study is to study if an investigational drug (one that is not FDA approved), named sparsentan, will help in the ...Phase
Interventional
